Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Ataxia Neuropathy Spectrum Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Ataxia Neuropathy Spectrum in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Renal Tubular Acidosis, Proximal, With Ocular Abnormalities and Mental Retardation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Renal Tubular Acidosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Myoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Myoma with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Joint Instability Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Joint Instability with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Myotonia Congenita Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Myotonia Congenita with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Congenital Fibrosis of the Extraocular Muscles Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Congenital Fibrosis of the in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Athabaskan Severe Combined Immunodeficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Athabaskan Severe Combined in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Ataxia Telangiectasia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Ataxia Telangiectasia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Early-Onset Ataxia With Oculomotor Apraxia and Hypoalbuminemia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Early-Onset Ataxia With in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Mandibular Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Mandibular Neoplasms with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Polycystic Kidneys, Severe Infantile With Tuberous Sclerosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Polycystic Kidneys, Severe in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Cystic Adenomatoid Malformation of Lung, Congenital Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Cystic Adenomatoid in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..